By day 29 of the trial, 11.2% in the remdesivir group and 11.3% in the control group had an adverse cardiac event.
Study shows no link between remdesivir, cardiac events
More from COVID-19More posts in COVID-19 »
- Study: Before vaccines, 44% of COVID-19 patients in ICU died
- Hospital COVID patients 35% more likely to die than flu patients last winter, study suggests
- FDA warns of false results from Cue Health COVID tests
- COVID patient testing, isolation of sick staff cut in-hospital viral spread, modeling study suggests